SyntheMed plans 2006 launch for cardiac surgery adhesion barrier:
This article was originally published in Clinica
SyntheMed, formerly Life Medical Sciences, says it has enrolled the first patient in a multicentre European trial testing its REPEL-CV adhesion barrier in cardiac surgery, in preparation for an anticipated 2006 EU product launch. The Oceanport, New Jersey firm is also testing the adhesion barrier in US trials designed to support a marketing application for the product. Post-operative adhesion formation can be a serious complication of open-heart surgery, the firm said, adding that REPEL-CV could become the first adhesion barrier approved by the FDA for use in cardiac surgery. The product targets an annual worldwide market opportunity estimated to be worth around $250m.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.